F197. Aripiprazole Lauroxil NanoCrystal® Dispersion: A Potential 1-Day Initiation Regimen for Long-Acting Aripiprazole Lauroxil

      Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia, currently requires 21 days of oral aripiprazole upon initiation. We report results from a phase 1 study investigating a NanoCrystal® dispersion formulation of AL (ALNCD) designed to enable rapid achievement of therapeutic levels of aripiprazole as a potential 1-day regimen.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Biological Psychiatry
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect